image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.701
1.59 %
$ 34.9 M
Market Cap
-3.05
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one NMTC stock under the worst case scenario is HIDDEN Compared to the current market price of 0.701 USD, NeuroOne Medical Technologies Corporation is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one NMTC stock under the base case scenario is HIDDEN Compared to the current market price of 0.701 USD, NeuroOne Medical Technologies Corporation is HIDDEN

This DCF valuation model was last updated on May, 8, 2025.

The intrinsic value of one NMTC stock under the best case scenario is HIDDEN Compared to the current market price of 0.701 USD, NeuroOne Medical Technologies Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NMTC

image
$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4Dec '24Dec '2420252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25
FINANCIALS
3.45 M REVENUE
76.86%
-11.9 M OPERATING INCOME
0.57%
-12.3 M NET INCOME
-3.87%
-11 M OPERATING CASH FLOW
14.55%
-120 K INVESTING CASH FLOW
-4.54%
7.27 M FINANCING CASH FLOW
-1.75%
3.27 M REVENUE
1102.48%
1.71 M OPERATING INCOME
160.75%
1.79 M NET INCOME
153.28%
208 K OPERATING CASH FLOW
107.80%
-24.4 K INVESTING CASH FLOW
33.84%
132 K FINANCING CASH FLOW
-94.81%
Balance Sheet NeuroOne Medical Technologies Corporation
image
Current Assets 4.63 M
Cash & Short-Term Investments 1.46 M
Receivables 177 K
Other Current Assets 2.99 M
Non-Current Assets 739 K
Long-Term Investments 0
PP&E 672 K
Other Non-Current Assets 67.3 K
27.19 %3.29 %55.76 %12.51 %Total Assets$5.4m
Current Liabilities 2.21 M
Accounts Payable 1.03 M
Short-Term Debt 0
Other Current Liabilities 1.18 M
Non-Current Liabilities 2.33 M
Long-Term Debt 0
Other Non-Current Liabilities 2.33 M
22.63 %26.03 %51.34 %Total Liabilities$4.5m
EFFICIENCY
Earnings Waterfall NeuroOne Medical Technologies Corporation
image
Revenue 3.45 M
Cost Of Revenue 2.37 M
Gross Profit 1.08 M
Operating Expenses 13 M
Operating Income -11.9 M
Other Expenses 431 K
Net Income -12.3 M
4m4m2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)3m(2m)1m(13m)(12m)(431k)(12m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
31.27% GROSS MARGIN
31.27%
-344.26% OPERATING MARGIN
-344.26%
-356.74% NET MARGIN
-356.74%
-1498.53% ROE
-1498.53%
-229.39% ROA
-229.39%
-376.57% ROIC
-376.57%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NeuroOne Medical Technologies Corporation
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income -12.3 M
Depreciation & Amortization 247 K
Capital Expenditures -120 K
Stock-Based Compensation 1.34 M
Change in Working Capital 0
Others -285 K
Free Cash Flow -11.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NeuroOne Medical Technologies Corporation
image
NMTC has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 18
6. Ownership
Insider Ownership NeuroOne Medical Technologies Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
150 K USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
NeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global Conference Eden Prairie, Minnesota--(Newsfile Corp. - May 5, 2025) - NeuroOne Medical (NASDAQ: NMTC), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May 14, 2025, at The Plaza Hotel in New York City. newsfilecorp.com - 2 months ago
NeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern Time EDEN PRAIRIE, Minn., May 01, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, will release financial results for its fiscal second quarter ended March 31, 2025, before market open on May 13, 2025. globenewswire.com - 2 months ago
NeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Multi-Contact Probe Provides Alternative to Pharmaceutical and Invasive Surgical Treatments Submission Completed Earlier Than Anticipated EDEN PRAIRIE, Minn., April 23, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has filed its 510(k) submission to the FDA for trigeminal nerve ablation earlier than previous guidance. globenewswire.com - 2 months ago
NeuroOne® Issues Letter to Shareholders Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. globenewswire.com - 2 months ago
NeuroOne® OneRF® Technology Success Story Featured on Fox News Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that its proprietary OneRF® Ablation System was recently featured in a national Fox News article highlighting the successful treatment of a pediatric epilepsy patient. globenewswire.com - 2 months ago
Nasdaq Dips 5%; NeuroOne Medical Technologies Shares Plummet U.S. stocks traded lower midway through trading, with the Dow Jones index dipping more than 1,100 points on Friday. Beijing unveiled a retaliatory 34% tariff on U.S. goods—mirroring the rate announced by President Donald Trump on Wednesday—deepening fears of a full-blown trade war. benzinga.com - 3 months ago
NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock EDEN PRAIRIE, Minn., April 04, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today the pricing of an underwritten registered public offering of 16,000,000 shares of its common stock at a price of $0.50 per share. globenewswire.com - 3 months ago
NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock EDEN PRAIRIE, Minn., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock. globenewswire.com - 3 months ago
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace - Update EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today's Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The discussion explored the latest advancements in epilepsy treatment and NeuroOne's breakthrough OneRF® Ablation System. globenewswire.com - 3 months ago
NeuroOne® CEO Dave Rosa Discusses Epilepsy Treatment Innovations on Today's Marketplace EDEN PRAIRIE, Minn., March 18, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that CEO Dave Rosa was featured on Today's Marketplace (TMP) alongside Dr. Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. globenewswire.com - 3 months ago
NeuroOne CEO Joins Today's Marketplace To Discuss The Latest Treatments for Epilepsy NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) --  Today's Marketplace (TMP) is proud to announce a featured interview with NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) CEO Dave Rosa and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss the latest treatments for epilepsy The full interview can be viewed online here. globenewswire.com - 3 months ago
NeuroOne® Accelerates Timeline of 510(k) Submission to FDA for the OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain Submission for New Intended Use That Leverages Company's Patented OneRF® Technology Platform Expected in May 2025  EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company's patented OneRF® Technology Platform. globenewswire.com - 3 months ago
8. Profile Summary

NeuroOne Medical Technologies Corporation NMTC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 34.9 M
Dividend Yield 0.00%
Description NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
Contact 7599 Anagram Drive, Eden Prairie, MN, 55344 https://n1mtc.com
IPO Date March 15, 2018
Employees 17
Officers Mr. Steven Mertens Chief Technology Officer Mr. David A. Rosa M.D. President, Chief Executive Officer & Director Mr. Hijaz Haris Vice President of Marketing Mr. Ronald W. McClurg Chief Financial Officer Mr. Mark Christianson Co-Founder, Business Development Director & Medical Sales Liaison Mr. Christopher R. Volker CFA Chief Operating Officer